StockGlow

Veru Inc. (VERU)

Develops medicines for cancer, metabolic diseases, and respiratory infections, plus female condoms.

$2.23-0.02%Healthcare
Compare VERU with
StockGlow Score
20
Leaning Bearish
BearishBullish
1 year ago-54.5%

The outlook

Veru is trading well below its 50- and 200-day moving averages and sits near its 52-week low. Analyst sentiment leans bearish overall, though the average price target sits roughly 10x the current price—a wide gap that reflects deep disagreement among analysts covering the stock.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +999% vs current price

Analyst price target

~12-month · 2 analysts
$24.50average target+998.7% vs now
Now $2.23
Low $24.00High $25.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$35.8M
52-wk high
$7.33
52-wk low
$2.05
50-day avg
$2.67
200-day avg
$2.61
Trailing P/E
—

Similar stocks

GLSIGreenwich LifeSciences, Inc.$13.45+0.07%FLNAFilana Therapeutics, Inc.$0.88-1.72%OCGNOcugen, Inc.$1.24-1.59%TTOOT2 Biosystems, Inc.$0.00+0.00%GOVXGeoVax Labs, Inc.$0.73-4.37%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy